NOVN N Stock Overview
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF1,719.29 |
| 52 Week High | CHF1,719.29 |
| 52 Week Low | CHF1,719.29 |
| Beta | 0.49 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -2.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOVN N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 0.3% |
| 1Y | n/a | -13.8% | 2.1% |
Return vs Industry: Insufficient data to determine how NOVN N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NOVN N performed against the MX Market.
Price Volatility
| NOVN N volatility | |
|---|---|
| NOVN N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.0% |
| 10% least volatile stocks in MX Market | 2.1% |
Stable Share Price: NOVN N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NOVN N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 103,000 | Vas Narasimhan | www.novartis.com |
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Novartis AG Fundamentals Summary
| NOVN N fundamental statistics | |
|---|---|
| Market cap | Mex$3.59t |
| Earnings (TTM) | Mex$136.93b |
| Revenue (TTM) | Mex$950.23b |
26.2x
P/E Ratio3.8x
P/S RatioIs NOVN N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVN N income statement (TTM) | |
|---|---|
| Revenue | US$53.07b |
| Cost of Revenue | US$15.31b |
| Gross Profit | US$37.76b |
| Other Expenses | US$30.11b |
| Earnings | US$7.65b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 24, 2023
| Earnings per share (EPS) | 3.70 |
| Gross Margin | 71.15% |
| Net Profit Margin | 14.41% |
| Debt/Equity Ratio | 51.1% |
How did NOVN N perform over the long term?
See historical performance and comparison